Business · 28/07/2021Updated: 10/17/2026 · 1 min read
Fresenius Kabi USA, LLC, et al. Withdraw FDA Approval of 15 Abbreviated New Drug Applications
Summary
The US Food and Drug Administration (FDA) is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, following written notifications that the drug products are no longer commercially available.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →